{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:35Z","timestamp":1780987955584,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005440","name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Loxo\/Lilly SRA"],"award-info":[{"award-number":["Loxo\/Lilly SRA"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01382-x","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:22:40Z","timestamp":1761582160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression"],"prefix":"10.1038","volume":"15","author":[{"given":"Shady I.","family":"Tantawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-8961","authenticated-orcid":false,"given":"Ganiraju","family":"Manyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaKesla R.","family":"Iles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6985-3509","authenticated-orcid":false,"given":"Natalia","family":"Timofeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9547-4193","authenticated-orcid":false,"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1157-6489","authenticated-orcid":false,"given":"Sai Prasad","family":"Desikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-270X","authenticated-orcid":false,"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-9166","authenticated-orcid":false,"given":"Varsha","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1382_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00675-9","volume":"12","author":"B Aslan","year":"2022","unstructured":"Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, et al. Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022;12:80.","journal-title":"Blood Cancer J"},{"key":"1382_CR2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2023-183029","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH. et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142:62\u201372.","journal-title":"Blood"},{"key":"1382_CR3","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1182\/bloodadvances.2023012360","volume":"8","author":"B Aslan","year":"2024","unstructured":"Aslan B, Manyam G, Iles LR, Tantawy SI, Desikan SP, Wierda WG, et al. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024;8:4487\u2013501.","journal-title":"Blood Adv"},{"key":"1382_CR4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397:892\u2013901.","journal-title":"Lancet"},{"key":"1382_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389:33\u201344.","journal-title":"N Engl J Med"},{"key":"1382_CR6","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","volume":"21","author":"F Cervantes-Gomez","year":"2015","unstructured":"Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21:3705\u201315.","journal-title":"Clin Cancer Res"},{"key":"1382_CR7","first-page":"92","volume":"110","author":"NN Shah","year":"2025","unstructured":"Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I\/II BRUIN trial. Haematologica. 2025;110:92\u2013102.","journal-title":"Haematologica"},{"key":"1382_CR8","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023;7:1929\u201343.","journal-title":"Blood Adv"},{"key":"1382_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med. 2022;386:735\u201343.","journal-title":"N Engl J Med"},{"key":"1382_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood.2024026672","volume":"145","author":"CS Tam","year":"2025","unstructured":"Tam CS, Balendran S, Blombery P. Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors. Blood. 2025;145:1005\u20139.","journal-title":"Blood"},{"key":"1382_CR11","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/s41375-023-01901-4","volume":"37","author":"PA Thompson","year":"2023","unstructured":"Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N. et al. Venetoclax consolidation in high-risk CLL treated with ibrutinib for\u00f2 1 year achieves a high rate of undetectable MRD. Leukemia. 2023;37:1444\u20131453.","journal-title":"Leukemia"},{"key":"1382_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","volume":"7","author":"N Jain","year":"2021","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7:1213\u20139.","journal-title":"JAMA Oncol"},{"key":"1382_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood-2019-131732","volume":"134","author":"N Jain","year":"2019","unstructured":"Jain N, Keating MJ, Thompson PA, Burger JA, Ferrajoli A, Estrov ZE, et al. Combined ibrutinib and venetoclax in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL). Blood. 2019;134:359.","journal-title":"Blood"},{"key":"1382_CR14","first-page":"3278","volume":"139","author":"P Ghia","year":"2022","unstructured":"Ghia P, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S. et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): primary analysis of the FD cohort of the phase 2 captivate study. Wolters Kluwer Health. 2022;139:3278\u20133289.","journal-title":"Wolters Kluwer Health"},{"key":"1382_CR15","doi-asserted-by":"publisher","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:EVIDoa2200006.","journal-title":"NEJM Evid"},{"key":"1382_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hon.3163_116","volume":"41","author":"K Patel","year":"2023","unstructured":"Patel K, Brown J, Desikan S, Nguyen B, Won H, Tantawy S, et al. Genomic evolution and resistance to pirtobrutinib in covalent btk-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase i\/ii bruin study. Hematol Oncol. 2023;41:185\u20137.","journal-title":"Hematol Oncol"},{"key":"1382_CR17","doi-asserted-by":"publisher","first-page":"1226289","DOI":"10.3389\/fonc.2023.1226289","volume":"13","author":"SI Tantawy","year":"2023","unstructured":"Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front Oncol. 2023;13:1226289","journal-title":"Front Oncol"},{"key":"1382_CR18","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2024-211454","volume":"144","author":"N Jain","year":"2024","unstructured":"Jain N, Ferrajoli A, Swaminathan M, Reville PK, Burger JA, Bharathi V, et al. Combined pirtobrutinib, venetoclax, and obinutuzumab as first-line treatment of patients with chronic lymphocytic leukemia (CLL). Blood. 2024;144:1011.","journal-title":"Blood"},{"key":"1382_CR19","doi-asserted-by":"publisher","first-page":"TPS7583-TPS","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7583","volume":"41","author":"TA Eyre","year":"2023","unstructured":"Eyre TA, Thompson P, Wierda WG, \u0160imkovi\u010d M, Grosicki S, Jurczak W, et al. BRUIN CLL-322: a phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol. 2023;41:TPS7583-TPS.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01382-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01382-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01382-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:06:45Z","timestamp":1761908805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01382-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01382-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6249480\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Specifically, for the current investigations, VG received a sponsored research agreement from Loxo Oncology (now a subsidiary of Lilly Oncology). Previously, for other investigations, VG received research funding from Pharmacyclics, Acerta, Gilead, Sunesis, Infinity, AbbVie, and Clear Creek Bio. WGW received research funding from GSK\/Novartis, AbbVie, Genentech, Pharmacyclics LLC, AstraZeneca\/Acerta Pharma, Gilead Sciences, Juno Therapeutics, KITE Pharma, Sunesis, Miragen, Oncternal Therapeutics, Inc., Cyclacel, Loxo Oncology, Inc., Janssen, Xencor. The remaining authors declare no competing financial interests. Consultancy\/honoraria: AbbVie, Ascentage, AstraZeneca, Beigene, Genmab, Janssen, Lilly, Merck. Speaker fees: AbbVie, AstraZeneca, Beigene, Janssen, Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}